Rare Disease: No HTA Approval? – No Problem!
Thursday 18th June 2026 13:00 - 14:00 (BST)
From national roadblock to local breakthrough: practical pathways to Rare Disease funding
Masterclass Details:
When a national commissioning recommendation seems out of reach due to stringent HTA thresholds or evidentiary gaps, the path to the patient doesn’t have to end.
In this 60-minute masterclass, market access expert Phil Cox explores the strategic alternatives available when standard NICE or SMC pathways stall; when focus shifts from ‘broad access’ to ‘targeted impact’ and understanding sub-national options can lead to commercial success, allowing for limited but life-transforming local NHS funding streams.
The session includes a roadmap for navigating Individual Funding Requests and clinical exceptionality criteria. Discover strategies for partnering to develop local commissioning policies and explore how shared care can be a viable option.
If you’re navigating a challenging launch or a negative HTA outcome, this masterclass will equip you with practical, commercially grounded approaches to secure meaningful patient access – even without national approval.
Join live to ask your questions and move from setback to solution with pragmatic, actionable patient access strategies.
Key Learning Objectives:
- Learn how to shift focus from broad market access to securing high-impact funding for the most severely affected patients
- Understand how to pivot from national HTA roadblocks towards sub-national and local NHS funding opportunities
- Identify non-traditional access pathways, including their strategic advantages, limitations and practical implications
- Discover a practical roadmap to success, considering the pros and cons of the available options
LSAA reserves the right to restrict access to this webinar to LSAA members.
-
Date and time
18th Jun 2026 13:00 – 14:00 (BST)
